See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin, a selective inhibitor of oncogenic transcription, has been associated with certain side effects that have impacted its dosage frequency. The drug is used to treat metastatic small cell lung cancer (SCLC) and other solid tumors, but its use must be balanced against potential adverse reactions.

Common side effects of lurbinectedin include myelosuppression, particularly neutropenia and thrombocytopenia, as well as increased liver enzymes, nausea, and fatigue [1]. These side effects can be severe and have led to modifications in the dosage and administration of lurbinectedin.

Myelosuppression, in particular, has had a significant impact on the drug's dosage frequency. Severe neutropenia, characterized by an abnormally low number of neutrophils, can increase the risk of infection and has led to dose reductions or delays in treatment [1]. Similarly, thrombocytopenia, or a low platelet count, can increase the risk of bleeding and has also resulted in dose modifications [1].

The drug's manufacturer, PharmaMar, has provided guidelines for managing these side effects and adjusting the dosage of lurbinectedin accordingly [1]. These guidelines recommend monitoring blood counts and liver function tests regularly during treatment and adjusting the dosage or delaying treatment as necessary.

In summary, the side effects of lurbinectedin, particularly myelosuppression, have had a significant impact on the drug's dosage frequency. Close monitoring of blood counts and liver function tests is necessary to manage these side effects and adjust the dosage as needed.

Sources:

1. PharmaMar. (2021). Zepzelca (lurbinectedin) prescribing information. <https://www.pharmamar.com/en/profesionales/productos-autorizados/zepzelca-lurbinectedin/informacion-prescribir>